VIVUS Inc. (VVUS) Shares Spike Following FDA Approval

Shares of VIVUS Inc. (VVUS) gained more than 12% to $4.55 in morning trading on Thursday after the U.S. Food and Drug Administration approved the company’s new label impotence drug STENDRA, which cuts in half the time patients need to take the pill before engaging in sexual activity. Previously approved prescribing information recommended that patients […] View the full post at: VIVUS Inc. (VVUS) Shares Spike Following FDA Approval Related posts: Atlas Pipeline (APL) Shares Soar On Nat Gas Asset Sale Warren Buffett’s Holding Company Reduces Stake in Moody’s Shares Health is an R&D Problem
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.